Metlife Earnings Calls
| Release date | May 06, 2026 |
| EPS estimate | $2.27 |
| EPS actual | $2.42 |
| EPS Surprise | 6.61% |
| Revenue estimate | 19.487B |
| Revenue actual | 19.074B |
| Revenue Surprise | -2.12% |
| Release date | Feb 04, 2026 |
| EPS estimate | $2.34 |
| EPS actual | $2.49 |
| EPS Surprise | 6.41% |
| Revenue estimate | 27.218B |
| Revenue actual | 23.814B |
| Revenue Surprise | -12.51% |
| Release date | Nov 05, 2025 |
| EPS estimate | $2.32 |
| EPS actual | $1.34 |
| EPS Surprise | -42.24% |
| Revenue estimate | 18.803B |
| Revenue actual | 16.881B |
| Revenue Surprise | -10.22% |
| Release date | Aug 06, 2025 |
| EPS estimate | $2.15 |
| EPS actual | $1.08 |
| EPS Surprise | -49.77% |
| Revenue estimate | 18.69B |
| Revenue actual | 17.16B |
| Revenue Surprise | -8.19% |
Last 4 Quarters for Metlife
Below you can see how MET-PA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 06, 2025 |
| Price on release | $23.84 |
| EPS estimate | $2.15 |
| EPS actual | $1.08 |
| EPS surprise | -49.77% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $23.92 |
| Aug 01, 2025 | $23.83 |
| Aug 04, 2025 | $23.83 |
| Aug 05, 2025 | $23.92 |
| Aug 06, 2025 | $23.84 |
| Aug 07, 2025 | $23.84 |
| Aug 08, 2025 | $23.83 |
| Aug 11, 2025 | $23.95 |
| Aug 12, 2025 | $24.04 |
| 4 days before | -0.334% |
| 4 days after | 0.84% |
| On release day | 0.0025% |
| Change in period | 0.502% |
| Release date | Nov 05, 2025 |
| Price on release | $23.56 |
| EPS estimate | $2.32 |
| EPS actual | $1.34 |
| EPS surprise | -42.24% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $23.90 |
| Oct 31, 2025 | $23.88 |
| Nov 03, 2025 | $23.67 |
| Nov 04, 2025 | $23.52 |
| Nov 05, 2025 | $23.56 |
| Nov 06, 2025 | $23.55 |
| Nov 07, 2025 | $23.51 |
| Nov 10, 2025 | $23.50 |
| Nov 11, 2025 | $23.31 |
| 4 days before | -1.42% |
| 4 days after | -1.06% |
| On release day | -0.0424% |
| Change in period | -2.47% |
| Release date | Feb 04, 2026 |
| Price on release | $21.69 |
| EPS estimate | $2.34 |
| EPS actual | $2.49 |
| EPS surprise | 6.41% |
| Date | Price |
|---|---|
| Jan 29, 2026 | $21.68 |
| Jan 30, 2026 | $21.78 |
| Feb 02, 2026 | $21.74 |
| Feb 03, 2026 | $21.70 |
| Feb 04, 2026 | $21.69 |
| Feb 05, 2026 | $21.57 |
| Feb 06, 2026 | $21.64 |
| Feb 09, 2026 | $21.74 |
| Feb 10, 2026 | $21.92 |
| 4 days before | 0.0461% |
| 4 days after | 1.06% |
| On release day | -0.553% |
| Change in period | 1.11% |
| Release date | May 06, 2026 |
| Price on release | $21.76 |
| EPS estimate | $2.27 |
| EPS actual | $2.42 |
| EPS surprise | 6.61% |
| Date | Price |
|---|---|
| Apr 30, 2026 | $21.17 |
| May 01, 2026 | $21.38 |
| May 04, 2026 | $21.40 |
| May 05, 2026 | $21.54 |
| May 06, 2026 | $21.76 |
| May 07, 2026 | $21.78 |
| May 08, 2026 | $21.81 |
| May 11, 2026 | $21.88 |
| May 12, 2026 | $22.20 |
| 4 days before | 2.79% |
| 4 days after | 2.02% |
| On release day | 0.0919% |
| Change in period | 4.87% |
Metlife Earnings Call Transcript Summary of Q1 2026
MetLife reported a strong Q1 2026: adjusted earnings of $1.6 billion ($2.42 per share), up 18% YoY (adjusted EPS +23%), with adjusted ROE at 17% (top end of the 15–17% target) and a direct expense ratio of 11.9% (better than the 12.1% annual target). Revenue growth was broad-based across segments: Group Benefits (+19% adjusted earnings; sales +15%), Retirement & Income Solutions (+11%; continued strength in pension risk transfer and reinsurance products), Asia (+31%; sales +22 on constant currency, with Japan and Korea strong), Latin America (+5%) and EMEA (+33%). Variable investment income (VII) was $518 million pretax, driven by strong private equity/venture returns (private equity avg. quarterly return ~2.9%). MetLife closed its first fully integrated quarter post-PineBridge acquisition for MIM; MIM adjusted earnings improved but saw modest short-term institutional outflows while pipeline and cross‑sell opportunities look solid. Capital actions included ~$750 million of share repurchases, ~$370 million of dividends in the quarter (~$1.1 billion returned), a subsequent ~$200 million repurchase in April, $1.1 billion remaining repurchase authorization, a 4.4% dividend increase, and a $1 billion subordinated debt issuance. Balance sheet and liquidity remain solid (holding company cash ~$3.9 billion; U.S. NAIC RBC ~379%). Management highlighted continued AI and tech modernization investments (> $3.2 billion over 5 years), disciplined underwriting, selective asset allocation in private assets (private fixed income ~$85 billion; ~95% investment grade; limited exposure to high-risk segments), and continued focus on margin and pricing discipline. Notable points/risks: divestiture of Ukraine business, ongoing regulatory conversations in Japan (industry-wide issue) but no material operational impact reported, seasonality and some near-term volatility in investment trading and statutory capital due to dividends, and temporary MIM outflows post-acquisition. Management reiterated confidence in the New Frontier strategy and the company’s ability to deliver durable earnings and disciplined capital returns.
Sign In
Buy MET-PA